{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"67","value":"49"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"description":"Time to Next Therapy is the duration of time from of starting ibrutinib until next therapy. Participants were treated for 40 cycles and then followed for 2 years or until next therapy or death. Participants had the option to continue ibrutinib commercially. 40 participants were censored while still on commercial ibrutinib therapy.","dispersionType":"Full Range","groups":[{"description":"PCI-32765; ibrutinib\n\nPCI-32765: Taken orally, once daily in the morning","id":"OG000","title":"Treatment Arm"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"6 years","title":"To Determine Time to Next Therapy (TTNT) of PCI-32765 in Symptomatic WM Patients With Relapsed/Refractory Disease","type":"SECONDARY","unitOfMeasure":"months"}